Update shared on25 Sep 2025
Fair value Increased 1.42%As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89.
What's in the News
- UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
- Teva launched a FDA-approved generic of Saxenda (liraglutide injection) in the U.S., targeting a market with $165 million in annual sales.
- The FDA approved AJOVY for preventive treatment of episodic migraine in children and adolescents, making it the first CGRP antagonist for pediatric migraine prevention and further broadening Teva’s neuroscience portfolio.
- Management reaffirmed 2025 revenue guidance of $16.8 billion to $17.2 billion.
- No shares were repurchased in Q2 2025; total buyback since 2011 remains at 57.6 million shares for $2.57 billion.
Valuation Changes
Summary of Valuation Changes for Teva Pharmaceutical Industries
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $23.56 to $23.89.
- The Future P/E for Teva Pharmaceutical Industries remained effectively unchanged, moving only marginally from 24.39x to 24.73x.
- The Consensus Revenue Growth forecasts for Teva Pharmaceutical Industries remained effectively unchanged, at 2.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.